Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 0.78 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.78 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.78 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.78 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.78 |
| ▸ | HRH1 | P35367 | 4/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxapine SCHEMBL5500954 | 0.90 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL41643 | 0.90 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL30201498 | 0.90 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL29414130 | 0.90 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL3674535 | 0.89 | HRH4 (0.95) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL94146 | 0.89 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL29482385 | 0.89 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL19386241 | 0.89 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL30324780 | 0.89 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL29374082 | 0.89 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3447 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240295545-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240180881-A1 | METHODS FOR DECREASING RESISTANCE TO CHEMOTHERAPY | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2024-06-06 | — | — | US | claimed |
| EP-4291900-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-12-20 | — | — | EP | claimed |
| WO-2022172024-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-08-18 | — | — | WO | claimed |
| US-11253594-B2 | Drug combinations for protecting against neuronal cell death | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-22 | — | — | US | claimed |
| EP-3746138-A1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | Alexza Pharmaceuticals, Inc. (US) | 2020-12-09 | — | — | EP | claimed |
| US-20200129621-A1 | DRUG COMBINATIONS FOR PROTECTING AGAINST NEURONAL CELL DEATH | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-04-30 | — | — | US | claimed |
| WO-2019152873-A1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | ALEXZA PHARMACEUTICALS, INC. (US) | 2019-08-08 | — | — | WO | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | claimed |
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | ZALICUS INC. | 2003-04-24 | — | — | US | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| WO-2003006026-A1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-01-23 | — | — | WO | claimed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-6187752-B1 | Method for treating schizophrenia employing an ace inhibitor | E.R. SQUIBB & SONS, INC. | 2001-02-13 | — | — | US | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |